olokizumab: Clinical Trials

19 trials of olokizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 9 Phase 3, 8 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 39Completed 5, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 28Completed 4, Terminated 2, Withdrawn 2
Phase 14Completed 4

Follow olokizumab: new trials by email Literature Review of olokizumab trials Research Report on olokizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
Placebo, Goflikicept, Olokizumab - Still Disease
Phase 3Not yet recruitingR-Pharm International, LLC522026-05-182026-06-04
Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)
Olokizumab, Placebo - Polymyalgia Rheumatica
Phase 3Active not recruitingR-Pharm International, LLC1252025-06-112026-06-30
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab, Omeprazole, Caffeine - Rheumatoid Arthritis
Phase 1CompletedR-Pharm International, LLC172021-11-162024-08-15
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
Olokizumab, Standard therapy - COVID-19
CompletedR-Pharm30872021-07-142023-01-20
Study of Efficacy of Different Treatment Regimens of Olokizumab
Olokizumab, Standard therapy - COVID-19
Phase 3UnknownR-Pharm1982021-07-082023-02-13
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
Olokizumab 64 mg, Placebo - COVID-19
Phase 2 / Phase 3WithdrawnR-Pharm2020-06-302021-11-08
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
RPH-104 80 mg, Olokizumab 64 mg, Placebo - COVID-19
Phase 2 / Phase 3CompletedR-Pharm International, LLC3722020-04-232022-01-24
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment - Rheumatoid Arthritis
Phase 3CompletedR-Pharm International, LLC21062017-07-042023-10-12
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
Olokizumab, Placebo - Rheumatoid Arthritis
Phase 3CompletedR-Pharm International, LLC3682017-01-252023-09-21
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w - Rheumatoid Arthritis
Phase 3CompletedR-Pharm International, LLC16482016-06-062023-09-21
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
Olokizumab, Placebo - Rheumatoid Arthritis
Phase 3CompletedR-Pharm International, LLC4282016-05-192023-09-21
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
Olokizumab (OKZ), Placebo - Crohn's Disease
Phase 2WithdrawnUCB BIOSCIENCES GmbH2012-06-012012-10-30
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
CDP6038 (olokizumab) - Rheumatoid Arthritis
Phase 2TerminatedUCB BIOSCIENCES, Inc.1032012-01-262022-05-20
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Placebo, Olokizumab 60 mg, Olokizumab 120 mg - Rheumatoid Arthritis
Phase 2CompletedUCB Japan Co. Ltd.1192011-10-012013-03-25
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
CDP6038 (olokizumab) - Rheumatoid Arthritis
Phase 2TerminatedUCB BIOSCIENCES, Inc.1902011-03-072022-04-14
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc - Rheumatoid Arthritis
Phase 2CompletedUCB Pharma2212010-11-012024-07-17
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects
CDP6038, Placebo - Healthy Volunteers
Phase 1CompletedUCB Pharma202010-11-012011-09-27
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
CDP6038, Placebo IV, Placebo SC - Arthritis, Rheumatoid Arthritis
Phase 1 / Phase 2CompletedUCB Pharma402009-10-012024-11-15
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
CDP6038, Placebo - Pharmacokinetics
Phase 1CompletedUCB Pharma672008-09-012012-03-22

Conditions studied

Arthritis, Rheumatoid (10)  ·  COVID-19 (4)  ·  Coronavirus Infections (3)  ·  Lung Diseases (2)  ·  Respiration Disorders (2)  ·  Arthritis (1)  ·  Arthritis, Juvenile (1)  ·  Crohn Disease (1)  ·  Lymphoma, Follicular (1)  ·  Polymyalgia Rheumatica (1)

Sponsors

R-Pharm International, LLC (8)  ·  UCB Pharma (4)  ·  R-Pharm (3)  ·  UCB BIOSCIENCES, Inc. (2)  ·  UCB BIOSCIENCES GmbH (1)  ·  UCB Japan Co. Ltd. (1)

Countries

Russia (9)  ·  United States (6)  ·  Germany (5)  ·  South Korea (5)  ·  United Kingdom (5)  ·  Bulgaria (4)  ·  Taiwan (4)  ·  Argentina (3)  ·  Brazil (3)  ·  Colombia (3)  ·  Czechia (3)  ·  Hungary (3)  ·  Mexico (3)  ·  Poland (3)  ·  Belarus (2)

Top investigators

Mikhail Samsonov (11)  ·  Mark Genovese, Dr (1)  ·  Tsutomu Takeuchi, Professor (1)

Results publications

PMID 42142212, PMID 24641941, PMID 26358841, PMID 34344706, PMID 36001712, PMID 36109142, PMID 41239458

NIH funding

2015 (2), 2009 (1), 2014 (1)